(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in included Trials for Fulton index Due to Pandemic-Related Challenges, Manufacturing Considerations
(10% Negative) Ultragenyx Pharmaceutical Inc. (RARE) Announces Delay in treatments Development Timeline Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment